Cell & Gene: The Podcast
by Erin Harris
Advancing CGT Delivery, Regulatory Strategy with Axiom's Dr. Remo…
About this podcast
Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
Episodes
The newest 20 of 149 episodes
- Advancing CGT Delivery, Regulatory Strategy with Axiom's Dr. Remo Moomiaie-Qajar · 13 minWe love to hear from our listeners. Send us a message. In Episode 140 of Cell & Gene: The Podcast, Erin Harris speaks with Dr. Remo Moomiaie-Qajar of Axiom Biosciences about the…
- Advancing Cell Therapy Toward a Functional Cure for T1D With Forthcoming BetaNova's Jonathan Rigby and Will Rust, Ph.D. · 25 minWe love to hear from our listeners. Send us a message. On episode 139, Host Erin Harris talks to Jonathan Rigby, President and CEO of Sernova (and proposed CEO of BetaNova) and…
- Structuring CGT Deals for the Long Term with Troutman Pepper Locke's EA Weeks, J.D., Ph.D. · 28 minWe love to hear from our listeners. Send us a message. In episode 138 of Cell & Gene: The Podcast, EA Weeks, J.D., Ph.D., Counsel at Troutman Pepper Locke talks to Host Erin…
- Shaping Drug Development by Starting with the Disease with Roche's Sylke Poehling, Ph.D. · 19 minWe love to hear from our listeners. Send us a message. In episode 137 of Cell & Gene: The Podcast, Host Erin Harris talks with Sylke Poehling, Ph.D., SVP and Global Head…
- Why Autoimmune CAR T Needs a New Patient-Centered Playbook with Dr. Panteli Theocharous · 40 minWe love to hear from our listeners. Send us a message. On episode 136 of Cell & Gene: The Podcast, Host Erin Harris welcomes back Dr. Panteli Theocharous, FIBMS, M.S., Ph.D…
- Reimagining Solid Tumor Immunotherapy Through Engineered Tregs with CoRegen's Dr. Sonal Gupta · 16 minWe love to hear from our listeners. Send us a message. In Episode 135 of Cell & Gene: The Podcast, Host Erin Harris talks to Sonal Gupta, MD, PhD, Chief Medical Officer of…
- Rewriting the Playbook for Stargardt Disease with Atsena Therapeutics' Shannon Boye, Ph.D. · 18 minWe love to hear from our listeners. Send us a message. Episode 134 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Shannon Boye, PhD, Founder and CSO of…
- How Precision Oncology Is Redefining Cancer Drug Development with Aprea Therapeutics' Dr. Oren Gilad · 18 minWe love to hear from our listeners. Send us a message. Episode 133 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Aprea Therapeutics' CEO, Dr. Oren Gilad…
- Exploring Dendritic Cell Therapy for Solid Tumors with Diakonos Oncology's Jay Hartenbach · 23 minWe love to hear from our listeners. Send us a message. Episode 132 of Cell & Gene: The Podcast features Host, Erin Harris' conversation with Diakonos Oncology's President and…
- Cell & Gene: The Podcast Presents: Better Biopharma’s Editors’ Roundtable — A Midyear Look at the 2026 Life Sciences Industry · 1 h 25 minWe love to hear from our listeners. Send us a message. For episode 131 of Cell & Gene: The Podcast, we’re sharing a recent "Better Biopharma" roundtable that Erin Harris had the…
- Why In Vivo Therapies Are Moving Toward the Clinic with Ascidian Therapeutics' Dr. Mike Ehlers · 18 minWe love to hear from our listeners. Send us a message. In Episode 3 of our in vivo-focused special series of Cell & Gene: The Podcast, Ascidian Therapeutics' Founder, President…
- Reimagining In Vivo Gene Editing Through Base Editing and Targeted Delivery with Beam Therapeutics' Gopi Shanker, Ph.D. · 18 minWe love to hear from our listeners. Send us a message. In episode 2 of this four-part in vivo-focused special series of Cell & Gene: The Podcast, Host Erin Harris sits down with…
- Advancing CAR T for Drug-Free Remission in Autoimmune Disease with Kyverna Therapeutics’ Dr. Naji Gehchan · 23 minWe love to hear from our listeners. Send us a message. In episode 130 of Cell & Gene: The Podcast, Dr. Naji Gehchan, Chief Medical and Development Officer at Kyverna…
- The Future of In Vivo Gene Editing and Clinical Translation with Precision Biosciences' Cassie Gorsuch, Ph.D. · 32 minWe love to hear from our listeners. Send us a message. This is Episode 1 of a four-episode in vivo-focused special series of Cell & Gene: The Podcast. Host Erin Harris speaks…
- Redefining CAR-T Timing and Patient Access with Allogene Therapeutics' Dr. Zachary Roberts · 18 minWe love to hear from our listeners. Send us a message. In episode 129 of Cell & Gene: The Podcast, Host Erin Harris reconnects with Zachary Roberts, M.D., Ph.D., EVP of Research…
- Building Integrated cGMP Systems for Autologous Cell Therapies with MassGen's Tatyana Matveeva, Ph.D. · 44 minWe love to hear from our listeners. Send us a message. In episode 128, Host Erin Harris talks to Tatyana Matveeva, Ph.D., Director of cGMP Operations at George A. "Doc" Lopez, MD…
- Rewriting Disease Biology Through LSD1 Inhibition with Oryzon's Carlos Buesa, Ph.D. · 23 minWe love to hear from our listeners. Send us a message. On Episode 127 of Cell & Gene: The Podcast, Carlos Buesa, Ph.D., Founder and Chairman of the Board at Oryzon talks to Host…
- Advancing Early Detection in Rare Cancers with Catriona Jamieson, M.D., Ph.D. · 21 minWe love to hear from our listeners. Send us a message. On episode 126 of Cell & Gene: The Podcast, Host Erin Harris welcomes Catriona Jamieson, M.D., Ph.D, Director of the UC San…
- Regulatory Flexibility in CGT: Key Shifts and Implications with Monika Swietlicka · 27 minWe love to hear from our listeners. Send us a message. On episode 125 of Cell & Gene: The Podcast, Host Erin Harris talks to Halloran Consulting Group's Monika Swietlicka to…
- Scaling CRISPR for Rare Disease with Aurora Therapeutics' Dr. Edward Kaye · 28 minWe love to hear from our listeners. Send us a message. On episode 124 of Cell & Gene: The Podcast, Aurora Therapeutics' CEO Dr. Edward Kaye discusses the company’s strategy for…








